PhRMA, Drugmakers Find Duplicative Requirements in CMC Biologics Guidance

The FDA should avoid duplicating existing requirements in its updated guidance on chemistry, manufacturing and controls information for biologics, according to PhRMA and several drugmakers in comments to the agency.
Source: Drug Industry Daily